8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Application of quantitative DTI metrics in sporadic CJD

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Diffusion Weighted Imaging is extremely important for the diagnosis of probable sporadic Jakob–Creutzfeldt disease, the most common human prion disease. Although visual assessment of DWI MRI is critical diagnostically, a more objective, quantifiable approach might more precisely identify the precise pattern of brain involvement. Furthermore, a quantitative, systematic tracking of MRI changes occurring over time might provide insights regarding the underlying histopathological mechanisms of human prion disease and provide information useful for clinical trials. The purposes of this study were: 1) to describe quantitatively the average cross-sectional pattern of reduced mean diffusivity, fractional anisotropy, atrophy and T1 relaxation in the gray matter (GM) in sporadic Jakob–Creutzfeldt disease, 2) to study changes in mean diffusivity and atrophy over time and 3) to explore their relationship with clinical scales. Twenty-six sporadic Jakob–Creutzfeldt disease and nine control subjects had MRIs on the same scanner; seven sCJD subjects had a second scan after approximately two months. Cortical and subcortical gray matter regions were parcellated with Freesurfer. Average cortical thickness (or subcortical volume), T1-relaxiation and mean diffusivity from co-registered diffusion maps were calculated in each region for each subject. Quantitatively on cross-sectional analysis, certain brain regions were preferentially affected by reduced mean diffusivity (parietal, temporal lobes, posterior cingulate, thalamus and deep nuclei), but with relative sparing of the frontal and occipital lobes. Serial imaging, surprisingly showed that mean diffusivity did not have a linear or unidirectional reduction over time, but tended to decrease initially and then reverse and increase towards normalization. Furthermore, there was a strong correlation between worsening of patient clinical function (based on modified Barthel score) and increasing mean diffusivity.

          Highlights

          • Quantitative diffusion MRI in sporadic CJD shows preferential regional involvement.

          • Longitudinally, mean diffusivity (MD) does not change linearly or unidirectionally.

          • A “model” of MD change with disease progression is proposed.

          • Phases with increasing MD show significant worsening of clinical function.

          • Relative normalization of MD occurs in later phases of disease.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Longitudinal pattern of regional brain volume change differentiates normal aging from MCI.

          Neuroimaging measures have potential as surrogate markers of disease through identification of consistent features that occur prior to clinical symptoms. Despite numerous investigations, especially in relation to the transition to clinical impairment, the regional pattern of brain changes in clinically normal older adults has not been established. We predict that the regions that show early pathologic changes in association with Alzheimer disease will show accelerated volume loss in mild cognitive impairment (MCI) compared to normal aging. Through the Baltimore Longitudinal Study of Aging, we prospectively evaluated 138 nondemented individuals (age 64-86 years) annually for up to 10 consecutive years. Eighteen participants were diagnosed with MCI over the course of the study. Mixed-effects regression was used to compare regional brain volume trajectories of clinically normal individuals to those with MCI based on a total of 1,017 observations. All investigated volumes declined with normal aging (p < 0.05). Accelerated change with age was observed for ventricular CSF (vCSF), frontal gray matter, superior, middle, and medial frontal, and superior parietal regions (p < or = 0.04). The MCI group showed accelerated changes compared to normal controls in whole brain volume, vCSF, temporal gray matter, and orbitofrontal and temporal association cortices, including the hippocampus (p < or = 0.04). Although age-related regional volume loss is apparent and widespread in nondemented individuals, mild cognitive impairment is associated with a unique pattern of structural vulnerability reflected in differential volume loss in specific regions. Early identification of patterns of abnormality is of fundamental importance for detecting disease onset and tracking progression.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects.

            Phenotypic heterogeneity in sporadic Creutzfeldt-Jakob disease (sCJD) is well documented, but there is not yet a systematic classification of the disease variants. In a previous study, we showed that the polymorphic codon 129 of the prion protein gene (PRNP), and two types of protease-resistant prion protein (PrP(Sc)) with distinct physicochemical properties, are major determinants of these variants. To define the full spectrum of variants, we have examined a series of 300 sCJD patients. Clinical features, PRNP genotype, and PrP(Sc) properties were determined in all subjects. In 187, we also studied neuropathological features and immunohistochemical pattern of PrP(Sc) deposition. Seventy percent of subjects showed the classic CJD phenotype, PrP(Sc) type 1, and at least one methionine allele at codon 129; 25% of cases displayed the ataxic and kuru-plaque variants, associated to PrP(Sc) type 2, and valine homozygosity or heterozygosity at codon 129, respectively. Two additional variants, which included a thalamic form of CJD and a phenotype characterized by prominent dementia and cortical pathology, were linked to PrP(Sc) type 2 and methionine homozygosity. Finally, a rare phenotype characterized by progressive dementia was linked to PrP(Sc) type 1 and valine homozygosity. The present data demonstrate the existence of six phenotypic variants of sCJD. The physicochemical properties of PrP(Sc) in conjunction with the PRNP codon 129 genotype largely determine this phenotypic variability, and allow a molecular classification of the disease variants.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Sporadic human prion diseases: molecular insights and diagnosis.

              Human prion diseases can be sporadic, inherited, or acquired by infection. Distinct clinical and pathological characteristics separate sporadic diseases into three phenotypes: Creutzfeldt-Jakob disease (CJD), fatal insomnia, and variably protease-sensitive prionopathy. CJD accounts for more than 90% of all cases of sporadic prion disease; it is commonly categorised into five subtypes that can be distinguished according to leading clinical signs, histological lesions, and molecular traits of the pathogenic prion protein. Three subtypes affect prominently cognitive functions whereas the other two impair cerebellar motor activities. An accurate and timely diagnosis depends on careful clinical examination and early performance and interpretation of diagnostic tests, including electroencephalography, quantitative assessment of the surrogate markers 14-3-3, tau, and of the prion protein in the CSF, and neuroimaging. The reliability of CSF tests is improved when these tests are interpreted alongside neuroimaging data. Copyright © 2012 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Journal
                Neuroimage Clin
                Neuroimage Clin
                NeuroImage : Clinical
                Elsevier
                2213-1582
                31 January 2014
                31 January 2014
                2014
                : 4
                : 426-435
                Affiliations
                [a ]Department of Neurology, University of California, San Francisco (UCSF), San Francisco, CA, USA
                [b ]Department of Neuroradiology, C. Mondino National Neurological Institute, Pavia. University of Pavia, Italy
                [c ]Graduate Group in Bioengineering, UCSF, San Francisco, CA, USA
                [d ]Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA, USA
                [e ]Brain MRI 3T Mondino Research Center C. Mondino National Neurological Institute, Pavia, Italy
                [f ]Department of Epidemiology and Biostatistics, UCSF, San Francisco, CA, USA
                [g ]Institute for Neurodegenerative Diseases, University of California, San Francisco (UCSF), USA
                [h ]Department of Pathology, University of California, San Francisco (UCSF), USA
                [i ]Memory and Aging Center, Department of Neurology, University of California, San Francisco, (UCSF), USA
                Author notes
                [* ]Corresponding author at: Box 3206, University of California, San Francisco, San Francisco, CA 94143, USA. Tel.: + 1 415 476 2900; fax: + 1 415 476 2921. ecaverzasi@ 123456gmail.com
                [1]

                Nothing to disclose related to this paper.

                [2]

                Study concept and design, acquisition of data, analysis and interpretation, critical revision of the manuscript for important intellectual content.

                [3]

                Study concept and design, acquisition of data, analysis and interpretation, critical revision of the manuscript for important intellectual content, study supervision.

                [4]

                Study concept and design, acquisition of data, critical revision of the manuscript for important intellectual content.

                [5]

                Statistical analysis, interpretation, critical revision of the manuscript for important intellectual content.

                [6]

                Paid a consulting fee by UCSF CTSI consulting for manuscript statistical analysis.

                [7]

                Analysis and interpretation (statistical analysis).

                [8]

                Critical revision of the manuscript for important intellectual content.

                [9]

                Funded by the NIH (AG021601).

                [10]

                Analysis and interpretation.

                [11]

                Receives grant support from the NIH/NIA and has nothing to disclose related to this paper. Dr. Miller serves as a consultant for TauRx, Allon Therapeutics, Lilly USA LLC and Siemens Medical Solutions. He has also received a research grant from Novartis. He is on the Board of Directors for the John Douglas French Foundation for Alzheimer's Research and for The Larry L. Hillblom Foundation.

                [12]

                Critical revision of the manuscript for important intellectual content, study supervision.

                [13]

                Study supervision, critical revision of the manuscript for important intellectual content.

                [14]

                Analysis and interpretation, critical revision of the manuscript for important intellectual content.

                [15]

                Funded by the NIH/NIAR01 AG-031189, NIH/NIA K23 AG021989; NIH/NIA AG031220 and Michael J. Homer Family Fund. Dr. Geschwind has served as a consultant for Lundbeck Inc., MedaCorp, The Council of Advisors, and Neurophage.

                Article
                S2213-1582(14)00012-6
                10.1016/j.nicl.2014.01.011
                3950558
                24624328
                d99ed461-6f6e-4818-8ddb-bda8be929eea
                © 2014 The Authors
                History
                : 18 October 2013
                : 13 December 2013
                : 17 January 2014
                Categories
                Article

                creutzfeldt–jakob disease,prion disease,atrophy,dwi,scjd,md
                creutzfeldt–jakob disease, prion disease, atrophy, dwi, scjd, md

                Comments

                Comment on this article